Twist Bioscience shares rise after deal with Lilly’s TuneLab
Twist Bioscience said it signed a deal with Eli Lilly’s drug discovery platform Lilly TuneLab, sending TWST up 5% to $144.90 Wednesday. The stock has more than quadrupled over the past year.